Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis
- PMID: 7073148
- DOI: 10.7326/0003-4819-96-5-561
Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis
Abstract
The effect of prophylactic low-dose heparin on mortality was tested in 1358 consecutive patients admitted to the medical wards of an acute care hospital. Eligibility for treatment or exclusion was ascertained on admission by predefined contraindications. Eligible patients with even-number hospital records were assigned to treatment (5000 U twice daily), those with odd-number records served as controls. Because determination of eligibility was open to bias, evaluation of treatment was based on comparison of the total even-number group (669 patients, of which 411 were treated with heparin), and the total odd-number group (689 patients, none treated with heparin). Mortality was significantly lower in the even-number group-7.8% (52 of 669 patients) versus 10.9% (75 of 689 patients) in the odd-number group; the difference increased consistently with length of hospitalization (p = 0.025). The estimated reduction in mortality attributable to heparin was 31.1%. We believe that low-dose heparin prophylaxis is appropriate in all immobilized medical patients who are not at risk of bleeding.
Similar articles
-
Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline.Ann Intern Med. 2011 Nov 1;155(9):602-15. doi: 10.7326/0003-4819-155-9-201111010-00008. Ann Intern Med. 2011. PMID: 22041949 Review.
-
Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group.Lancet. 1996 May 18;347(9012):1357-61. doi: 10.1016/s0140-6736(96)91009-0. Lancet. 1996. PMID: 8637340 Clinical Trial.
-
Venous thromboembolism prophylaxis in hospitalized heart failure patients.J Card Fail. 2008 Mar;14(2):127-32. doi: 10.1016/j.cardfail.2007.10.017. J Card Fail. 2008. PMID: 18325459
-
Effect of intravenous heparin administration on duration of hospitalization.Mayo Clin Proc. 2004 Feb;79(2):159-63. doi: 10.4065/79.2.159. Mayo Clin Proc. 2004. PMID: 14959908
-
Heparin-based treatment to prevent symptomatic deep venous thrombosis, pulmonary embolism or death in general medical inpatients is not supported by best evidence.Intern Med J. 2014 Nov;44(11):1054-65. doi: 10.1111/imj.12574. Intern Med J. 2014. PMID: 25367724 Review.
Cited by
-
Venous thromboembolism: epidemiology, diagnosis, prevention.J Gen Intern Med. 1986 Nov-Dec;1(6):402-11. doi: 10.1007/BF02596427. J Gen Intern Med. 1986. PMID: 3098941 Review. No abstract available.
-
Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.Intensive Care Med. 2009 Jul;35(7):1196-203. doi: 10.1007/s00134-009-1483-7. Epub 2009 Apr 15. Intensive Care Med. 2009. PMID: 19367397 Clinical Trial.
-
Management and prevention of venous thromboembolism including surgery and the pregnant state.Ochsner J. 2002 Winter;4(1):23-9. Ochsner J. 2002. PMID: 22822311 Free PMC article.
-
Prophylaxis of Venous Thrombosis.Curr Treat Options Cardiovasc Med. 2001 Jun;3(3):225-235. doi: 10.1007/s11936-001-0041-6. Curr Treat Options Cardiovasc Med. 2001. PMID: 11341868
-
Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells.Cancer Sci. 2013 Jun;104(6):740-9. doi: 10.1111/cas.12133. Epub 2013 Mar 24. Cancer Sci. 2013. PMID: 23421467 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical